KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.
Recombinant KSAC and L110f are promising Leishmania vaccine candidates. Both antigens formulated in stable emulsions (SE) with the natural TLR4 agonist MPL® and L110f with the synthetic TLR4 agonist GLA in SE protected BALB/c mice against L. major infection following needle challenge. Considering th...
Published in: | PLoS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0001610 https://doaj.org/article/66b7d8e5ac65409893efed54deb33b20 |
id |
ftdoajarticles:oai:doaj.org/article:66b7d8e5ac65409893efed54deb33b20 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:66b7d8e5ac65409893efed54deb33b20 2023-05-15T15:08:37+02:00 KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. Regis Gomes Clarissa Teixeira Fabiano Oliveira Phillip G Lawyer Dia-Eldin Elnaiem Claudio Meneses Yasuyuki Goto Ajay Bhatia Randall F Howard Steven G Reed Jesus G Valenzuela Shaden Kamhawi 2012-01-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0001610 https://doaj.org/article/66b7d8e5ac65409893efed54deb33b20 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC3317914?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0001610 https://doaj.org/article/66b7d8e5ac65409893efed54deb33b20 PLoS Neglected Tropical Diseases, Vol 6, Iss 4, p e1610 (2012) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2012 ftdoajarticles https://doi.org/10.1371/journal.pntd.0001610 2022-12-31T03:21:51Z Recombinant KSAC and L110f are promising Leishmania vaccine candidates. Both antigens formulated in stable emulsions (SE) with the natural TLR4 agonist MPL® and L110f with the synthetic TLR4 agonist GLA in SE protected BALB/c mice against L. major infection following needle challenge. Considering the virulence of vector-transmitted Leishmania infections, we vaccinated BALB/c mice with either KSAC+GLA-SE or L110f+GLA-SE to assess protection against L. major transmitted via its vector Phlebotomus duboscqi.Mice receiving the KSAC or L110f vaccines were challenged by needle or L. major-infected sand flies. Weekly disease progression and terminal parasite loads were determined. Immunological responses to KSAC, L110f, or soluble Leishmania antigen (SLA) were assessed throughout vaccination, three and twelve weeks after immunization, and one week post-challenge.Following sand fly challenge, KSAC-vaccinated mice were protected while L110f-vaccinated animals showed partial protection. Protection correlated with the ability of SLA to induce IFN-γ-producing CD4(+)CD62L(low)CCR7(low) effector memory T cells pre- and post-sand fly challenge.This study demonstrates the protective efficacy of KSAC+GLA-SE against sand fly challenge; the importance of vector-transmitted challenge in evaluating vaccine candidates against Leishmania infection; and the necessity of a rapid potent Th1 response against Leishmania to attain true protection. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLoS Neglected Tropical Diseases 6 4 e1610 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Regis Gomes Clarissa Teixeira Fabiano Oliveira Phillip G Lawyer Dia-Eldin Elnaiem Claudio Meneses Yasuyuki Goto Ajay Bhatia Randall F Howard Steven G Reed Jesus G Valenzuela Shaden Kamhawi KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
Recombinant KSAC and L110f are promising Leishmania vaccine candidates. Both antigens formulated in stable emulsions (SE) with the natural TLR4 agonist MPL® and L110f with the synthetic TLR4 agonist GLA in SE protected BALB/c mice against L. major infection following needle challenge. Considering the virulence of vector-transmitted Leishmania infections, we vaccinated BALB/c mice with either KSAC+GLA-SE or L110f+GLA-SE to assess protection against L. major transmitted via its vector Phlebotomus duboscqi.Mice receiving the KSAC or L110f vaccines were challenged by needle or L. major-infected sand flies. Weekly disease progression and terminal parasite loads were determined. Immunological responses to KSAC, L110f, or soluble Leishmania antigen (SLA) were assessed throughout vaccination, three and twelve weeks after immunization, and one week post-challenge.Following sand fly challenge, KSAC-vaccinated mice were protected while L110f-vaccinated animals showed partial protection. Protection correlated with the ability of SLA to induce IFN-γ-producing CD4(+)CD62L(low)CCR7(low) effector memory T cells pre- and post-sand fly challenge.This study demonstrates the protective efficacy of KSAC+GLA-SE against sand fly challenge; the importance of vector-transmitted challenge in evaluating vaccine candidates against Leishmania infection; and the necessity of a rapid potent Th1 response against Leishmania to attain true protection. |
format |
Article in Journal/Newspaper |
author |
Regis Gomes Clarissa Teixeira Fabiano Oliveira Phillip G Lawyer Dia-Eldin Elnaiem Claudio Meneses Yasuyuki Goto Ajay Bhatia Randall F Howard Steven G Reed Jesus G Valenzuela Shaden Kamhawi |
author_facet |
Regis Gomes Clarissa Teixeira Fabiano Oliveira Phillip G Lawyer Dia-Eldin Elnaiem Claudio Meneses Yasuyuki Goto Ajay Bhatia Randall F Howard Steven G Reed Jesus G Valenzuela Shaden Kamhawi |
author_sort |
Regis Gomes |
title |
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
title_short |
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
title_full |
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
title_fullStr |
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
title_full_unstemmed |
KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi. |
title_sort |
ksac, a defined leishmania antigen, plus adjuvant protects against the virulence of l. major transmitted by its natural vector phlebotomus duboscqi. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2012 |
url |
https://doi.org/10.1371/journal.pntd.0001610 https://doaj.org/article/66b7d8e5ac65409893efed54deb33b20 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 6, Iss 4, p e1610 (2012) |
op_relation |
http://europepmc.org/articles/PMC3317914?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0001610 https://doaj.org/article/66b7d8e5ac65409893efed54deb33b20 |
op_doi |
https://doi.org/10.1371/journal.pntd.0001610 |
container_title |
PLoS Neglected Tropical Diseases |
container_volume |
6 |
container_issue |
4 |
container_start_page |
e1610 |
_version_ |
1766339947706449920 |